Why the study?
Does enoxaparin 40 mg once daily provide a cost-effective alternative to unfractionated heparin or no prophylaxis for VTE prevention in acutely ill medical patients?
Does enoxaparin 40 mg once daily provide a cost-effective alternative to unfractionated heparin or no prophylaxis for VTE prevention in acutely ill medical patients?
Enoxaparin 40 mg once daily is cost-effective compared to no prophylaxis and cost-neutral compared to unfractionated heparin for VTE prevention in acutely ill medical patients.
No takes yet. Share an insight, caveat, or question.
Supports enoxaparin 40 mg daily as cost-effective VTE prophylaxis in medical inpatients; extends trial data favoring LMWH over UFH.
Lloyd et al. (2001) studied this question.